Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 10/20 | 0.35 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613860 | 0.84 | TP53 (0.38) | DRD2 | |
| SCHEMBL7619637 | 0.83 | DRD2 (0.40) | DRD2RORC | |
| SCHEMBL24437292 | 0.80 | MAPK14 (0.34) | DRD2RORCNR1I3CA12CA1 | |
| SCHEMBL5889844 | 0.75 | SIGMAR1 (0.34) | DRD2 | |
| SCHEMBL4500892 | 0.66 | P2RY14 (0.38) | DRD2NR1I3CA12CA1CA9 | |
| SCHEMBL16348810 | 0.65 | CNR2 (0.37) | DRD2RORCCA12CA1CA9 | |
| SCHEMBL12300356 | 0.65 | KCNQ4 (0.41) | RORC | |
| SCHEMBL14099787 | 0.65 | CNR2 (0.39) | CA12CA1CA9 | |
| SCHEMBL24630430 | 0.65 | CNR2 (0.48) | — | |
| SCHEMBL2392134 | 0.64 | HDAC3 (0.39) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | GENELABS TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002062755-A2 | POLYAMIDE ANALOGS AS DNA MINOR GROOVE BINDERS | GENELABS TECHNOLOGIES, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | CYP51A1, HDAC6, ERG28 | DRD2 4627/4885RORC 3987/4885NR1I3 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.